Optimer Pharmaceuticals (OPTR)
Optimer Pharmaceuticals R&D Expense: 11.07M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
OPTR R&D Expense Rankings
| Overall | 30th percentile | 1216 of 1762 |
| Sector | 31st percentile | 284 of 415 in Healthcare |
| Industry | 34th percentile | 99 of 151 in Biotechnology |
OPTR R&D Expense Range, Past 5 Years
| Minimum | 5.496M | Sep 2007 |
| Maximum | 13.73M | Dec 2011 |
| Average | 8.485M |
About R&D Expense
R&D expenses are a line item from many companies' income statements.
R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.
Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.
An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More
You may also be interested in these OPTR related companies
OPTR News
Market Wrap Video + Additions to Watch List http://stks.co/3vqH including: $MMR $MDF $WG $CODE $AZPN $OPTR $KEM
about 9 days ago by StockTiger
about 9 days ago by StockTiger
Market Wrap Video + Additions to Watch List http://stks.co/3vUp including: $MMR $MDF $WG $CODE $AZPN $OPTR $KEM
about 10 days ago by StockTiger
about 10 days ago by StockTiger
RT @TheEquitiesRoom: Stocks trading down to 20d support: $EIX $DRI $SWI $BMC $OPTR $BMRN $HSY < nice list
about 11 days ago by 1nvestor
about 11 days ago by 1nvestor
From Earlier: Optimer Pharmaceuticals Announces Analysis of Data from Two Phase 3 Studies Shows
May 17, 6:57AM Benzinga
May 17, 6:57AM Benzinga
EBR: Watchlist/worksheet/4 Trading Ideas: $OPTR $ACHN $BEAM $V http://stks.co/3pOI
about 16 days ago by TheEquitiesRoom
about 16 days ago by TheEquitiesRoom
ThinkEquity Assumes Optimer Pharma (OPTR) at Buy, Sets $25 Price Target
May 14, 11:04AM Street Insider
May 14, 11:04AM Street Insider
Oppenheimer Reiterates Outperform Rating, $20 PT for Optimer Pharmaceuticals
May 11, 6:06PM Benzinga
May 11, 6:06PM Benzinga
Listen to $OPTR Q1 2012 earnings call - live at 05:00 PM, ondemand after - http://stks.co/3mFh
about 21 days ago by earningscast
about 21 days ago by earningscast
Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
May 03, 8:00AM PR Newswire
May 03, 8:00AM PR Newswire
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 01, 4:00PM PR Newswire
May 01, 4:00PM PR Newswire
Optimer Pharma $OPTR heavy upside volume so far today with stock up 5.4%
about 36 days ago by zerosum24
about 36 days ago by zerosum24
$OPTR Upside Blowoff - 15 Minute Down Reversal - Red bar after 4 higher highs and higher lows
about 36 days ago by TradeIdeasQuant
about 36 days ago by TradeIdeasQuant
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2012 Financial Results
Apr 25, 8:00AM PR Newswire
Apr 25, 8:00AM PR Newswire
Harwood Feffer LLP Announces Investigation of Optimer Pharmaceuticals, Inc.
Apr 11, 12:07PM PR Newswire
Apr 11, 12:07PM PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Optimer Pharmaceuticals, Inc.
Apr 11, 8:30AM PR Newswire
Apr 11, 8:30AM PR Newswire
$OPTR 200 Day SMA Cross - Price crossed above 200 day SMA (12.2424). Confirmed by volume.
about 51 days ago by TradeIdeasQuant
about 51 days ago by TradeIdeasQuant
$OPTR is -5.1% down since open on unusual high volume and -10.1% down since close.
about 51 days ago by TradeBot
about 51 days ago by TradeBot
Needham & Company reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Mgmt Changes Not Related to Dificid
Apr 09, 3:00PM Street Insider
Apr 09, 3:00PM Street Insider
JMP Says Executive Removals Will Not Materially Impact Optimer (OPTR)
Apr 09, 12:58PM Street Insider
Apr 09, 12:58PM Street Insider
$TARO $PRGO $TEVA $OPTR - Pipeline upside, 20F and 6k Filings, Interesting price movement on Friday -> http://stks.co/3GRD
about 52 days ago by imhobutdydd
about 52 days ago by imhobutdydd
$OPTR removed Chang as Chairman, terminated Prunty as CFO and Shue as VP. Names Hank McKinnell as new Chair
about 52 days ago by Street_Insider
about 52 days ago by Street_Insider
Optimer Pharma (OPTR) Names Hank McKinnell as Chairman; Sees Q1 Revs Below Views
Apr 09, 7:08AM Street Insider
Apr 09, 7:08AM Street Insider
Optimer Pharmaceuticals Appoints New chairman; Sees Q1 Revenues $16.45M vs $29.44M Est
Apr 09, 7:03AM Benzinga
Apr 09, 7:03AM Benzinga
$OPTR http://stks.co/39B8 Long set-up; On watch for a trade over $14.15
about 63 days ago by amitp_gupta
about 63 days ago by amitp_gupta
$OPTR Upside Blowoff - 15 Minute Down Reversal - Red bar after 6 green bars
about 84 days ago by TradeIdeasQuant
about 84 days ago by TradeIdeasQuant
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| OPTR | 14.95 | -0.18 | -1.19% | 707.33M |
| OPNT | 24.96 | -0.68 | -2.65% | 578.44M |
| OPLK | 12.81 | +0.14 | +1.10% | 243.52M |
| OPHC | 0.6402 | -0.02 | -3.29% | 14.65M |
| OPEN | 39.64 | +0.00 | +0.00% | 893.88M |
